Ionis Pharmaceuticals Drops Another After Phase 3 Setback
Ionis Pharmaceuticals dropped again after a Phase 3 failure in transthyretin amyloid cardiomyopathy, triggering a bro...
We compare expense ratios across dividend growth ETFs to identify the lowest-cost options for long-term investing.
28,176 articlesIonis Pharmaceuticals dropped again after a Phase 3 failure in transthyretin amyloid cardiomyopathy, triggering a bro...
Oil prices surged after ships halted near Hormuz amid Iranian warnings, signaling a potential energy shock for househ...
Crypto dollars are moving from the sidelines to the heart of American politics, with record 2024 spending and a growi...
Bitcoin faces a looming quantum threat as experts warn Q-Day could arrive around 2030. Galaxy Digital's up-to-$5 mill...
The Bank Policy Institute is weighing legal action against the OCC to challenge national trust charters for crypto an...
AI verification flags a missing proof in a landmark 1976 economic theorem, risking a rethink of models relied upon in...
The federal civil rights agency voted 2-1 to terminate a 60-year-old workforce diversity reporting rule, a move that ...
Elon Musk has signaled an April roll-out for X Money's early public access, intensifying speculation about crypto fea...
Iovance Biotherapeutics has shown dramatic swings, with recent gains masking a long history of volatility. This piece...
Florida enters its worst drought in a generation, worsening the squeeze on citrus farmers already dealing with diseas...
Marking 100 days since the war began, negotiators say progress remains elusive. The standoff is spilling into energy ...
A major fund just boosted its stake in a struggling auto-parts retailer. This article breaks down what the move could...